Yüklüyor......
A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer
BACKGROUND: Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall surv...
Kaydedildi:
| Yayımlandı: | BMC Cancer |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5970460/ https://ncbi.nlm.nih.gov/pubmed/29801474 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4453-z |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|